Filing Flows › Integra Lifesciences Holdings (IART) › Q3 2026 › vs Q2 2026
Integra Lifesciences Holdings (IART) Q3 2026 vs Q2 2026 (quarter over quarter)
Integra Lifesciences Holdings's revenue fell $7.6M (-2%) from $419M in Q2 2026 to $411M in Q3 2026. The biggest changes: Specialty Surgery −$5.1M (-2%); Tissue Reconstruction −$2.4M (-2%). Operating margin 4.6% against 4.6% (-0.0 pts).
Integra Lifesciences Holdings, Q3 2026: revenue $411M (+2% year over year), operating margin 4.6%, net earnings $14.9M, operating cash flow $96.0M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 4.6% | 4.6% | -0.0 pts |
| Net margin | 3.6% | 1.1% | +2.5 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Specialty Surgery | $304M | $309M | −$5.1M | -2% |
| Tissue Reconstruction | $107M | $109M | −$2.4M | -2% |
| Revenue | $411M | $419M | −$7.6M | -2% |
| Operating profit | $18.9M | $19.3M | −$385K | -2% |
| Costs & expenses | $392M | $399M | −$7.2M | -2% |
| Pre-tax earnings | $15.7M | $4.7M | $10.9M | +230% |
| Other expense, net | $3.2M | $14.5M | −$11.3M | -78% |
| Cost of revenue | $201M | $199M | $2.3M | +1% |
| Research & development | $21.9M | $24.3M | −$2.4M | -10% |
| SG&A | $165M | $172M | −$7.1M | -4% |
| Other operating costs | $3.8M | $3.8M | −$12K | -0.3% |
| Net earnings | $14.9M | $4.5M | $10.4M | +231% |
| Income tax | $812K | $262K | $550K | +210% |
| Share-based compensation | $2.9M | $5.8M | −$2.9M | -50% |
| Working capital & other | $78.2M | $12.5M | $65.8M | +527% |
| Operating cash flow | $96.0M | $22.8M | $73.2M | +321% |
Questions
How much did Integra Lifesciences Holdings's revenue grow quarter over quarter in Q3 2026?
Integra Lifesciences Holdings's revenue fell $7.6M (-2%) from $419M in Q2 2026 to $411M in Q3 2026.
What drove Integra Lifesciences Holdings's revenue change in Q3 2026?
Specialty Surgery −$5.1M (-2%); Tissue Reconstruction −$2.4M (-2%).